Medline’s $2.7 billion stock sale puts demand for IPO favorite on the line
Medline Inc. shares held steady late Friday after its top holders priced a bigger secondary offering at $37 per share. The $2.68 billion deal offers investors a new signal on appetite for one of last year’s largest U.S. IPOs. The sale involves only existing shares, and Medline won’t get any money from it.